Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Ex vivo expanded human myeloid progenitor cells (hMPCs; CLT-008) have the potential to
accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in
patients receiving chemotherapy for acute lymphoblastic leukemia (ALL), acute myeloid
leukemia (AML), chronic myeloid leukemia (CML), or high-risk myelodysplasia (MDS). In this
study, the safety, tolerability and activity of CLT-008 administered after "standard of care"
cytarabine-based consolidation or induction/re-induction chemotherapy will be determined by
monitoring for adverse reactions, infusion reactions, graft-versus host disease (GVHD),
neutrophil and platelet recovery, hMPC persistence, infections and complications.